225 FRANKLIN STREET, BOSTON, MA
Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
Other Events
Financial Results, Reg. FD
Annual Report to Security Holders
Board Expansion and Appointment of John Doux, M.D. as Director
Investor Presentation
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Amended Registration Statement for Securities
Definitive Proxy Statement
Additional Proxy Materials
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload